J 2018

Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications

LEGRAND, M., P.O. LUDES, Z. MASSY, P. ROSSIGNOL, Jiří PAŘENICA et. al.

Základní údaje

Originální název

Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications

Autoři

LEGRAND, M. (250 Francie, garant), P.O. LUDES (250 Francie), Z. MASSY (250 Francie), P. ROSSIGNOL (250 Francie), Jiří PAŘENICA (203 Česká republika, domácí), J.J. PARK (410 Korejská republika), S. ISHIHARA (392 Japonsko), K.F. ALHABIB (682 Saúdská Arábie), A. MAGGIONI (380 Itálie), O. MIRO (724 Španělsko), N. SATO (392 Japonsko), A. COHEN-SOLAL (250 Francie), E. FAIRMAN (32 Argentina), J. LASSUS (246 Finsko), V.P. HARJOLA (246 Finsko), C. MUELLER (756 Švýcarsko), F. PEACOCK (840 Spojené státy), D.J. CHOI (410 Korejská republika), P. PLAISANCE (250 Francie), Jindřich ŠPINAR (203 Česká republika, domácí), M. KOSIBOROD (840 Spojené státy), A. MEBAZAA (250 Francie) a E. GAYAT (250 Francie)

Vydání

Clinical Research in Cardiology, Heidelberg, Springer, 2018, 1861-0684

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 4.907

Kód RIV

RIV/00216224:14110/18:00103657

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s00392-017-1173-3

UT WoS

000425730100003

Klíčová slova anglicky

Mortality; Potassium; B-blockers; Heart failure; Renal failure

Štítky

14110211, EL OK, rivok

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 9. 2. 2019 20:41, Soňa Böhmová

Anotace

V originále

Background The interaction between chronic medications on admission and the association between serum potassium level and outcome in patients with acute heart failure (AHF) are unknown. Methods Observational intercontinental study of patients admitted with AHF. 15954 patients were included from 12 cohorts in 4 continents. Main outcome was 90-day mortality. Clinical presentation (medication use, hemodynamics, comorbidities), demographic, echocardiographic, and biochemical data on admission were recorded prospectively in each cohort, with prospective adjudication of outcomes. Results Positive and negative linear relationships between 90-day mortality and sK+ above 4.5 mmol/L (hyperkalemia) and below 3.5 mmol/L (hypo-kalemia) were observed. Hazard ratio for death was 1.46 [1.34-1.58] for hyperkalemia and 1.22 [1.06-1.40] for hypokalemia. In a fully adjusted model, only hyperkalemia remained associated with mortality (HR 1.03 [1.02-1.04] for each 0.1 mmol/l change of sK+ above 4.5 mmol/L). Interaction tests revealed that the association between hyperkalemia and outcome was significantly affected by chronic medications. The association between hyperkalemia and mortality was absent for patients treated with beta blockers and in those with preserved renal function. Conclusions In patients with AHF, sK+ > 4.5 mmol/L appears to be associated with 90-day mortality. B-blockers have potentially a protective effect in the setting of hyperkalemia.
Zobrazeno: 5. 11. 2024 10:28